Meto review

What it is

Meto is a labs-gated compounded peptide platform. Its catalog runs four lab-matched stacks — GI Support, Muscle Preservation, Recovery and Joint, and Comprehensive Support — plus higher-intensity multi-peptide formulations for repair and for cognition and longevity, and nine individual peptides available à la carte: BPC-157, TB-500, sermorelin, NAD⁺, glutathione, GHK-Cu, thymosin α-1, epitalon and tesamorelin. It also offers compounded semaglutide and tirzepatide as one line among many. Care runs through independent licensed clinicians, medication is compounded by 503A pharmacies described as FDA-registered, batch-tested by an independent lab and shipped cold-chain. Note that this is a materially different business from the insurance-accepting metabolic GLP-1 service the brand previously ran; no insurance model appears on the site today.

How it works

Labs first, and the site is unusually direct about why: a two-minute questionnaire cannot see your inflammation, your metabolic markers or your growth-hormone axis, and a blood panel can. The sequence is a $149 Peptide Readiness Panel — or an upload of recent labs — then a protocol match, then a licensed clinician reads the file and signs off, usually stated as within 24 hours, then cold-chain delivery in three to five days. Membership adds quarterly video consults, unlimited secure messaging, weekly symptom logging with quarterly labs streaming to the clinician, protocol adjustments without a separate visit fee, and member pricing typically stated as 15 to 25 per cent below the à la carte rate. Pausing keeps your chart open for six months. This is a genuinely better-designed clinical loop than the category norm. The disclosure gaps are specific: no LegitScript or PCAB certification is displayed, the compounding pharmacy is named only by category, no state availability list is published, no medical leadership is identified, and the site displays its own aggregate ratings and patient counts, which we do not repeat. One formulation is flagged as unavailable pending FDA regulatory action, which is at least honest and worth noticing.

Pricing transparency

Two line items, both published, which is the clearest structure on this board. Membership is $29/month, or billed annually at a discount, and covers the clinician, dashboard and oversight regardless of how many peptides you are on. Medication is billed separately: BPC-157 $85/mo, glutathione $95/mo, sermorelin $120/mo, thymosin α-1 $140/mo, TB-500 $135/mo, GHK-Cu $135/mo, epitalon $165/mo, NAD⁺ $210/mo and tesamorelin $295/mo à la carte, with stacks from $175/mo for GI Support up to $319/mo for Comprehensive Support and $395/mo for the higher-intensity formulations. The lab panel is $149 on top. Because the membership and the medication are separate charges, we do not treat the headline peptide figure as a monthly floor — the real monthly cost is the sum, and the first month also carries the panel. Most protocols and the membership are stated as HSA/FSA eligible, and membership is month-to-month with pausing and cancellation from the dashboard.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Meto's own footer states that compounded medications and therapies available through it have not been approved by the FDA, that the FDA does not evaluate compounded medications for safety or efficacy, and that use involves known and unknown risks that vary from patient to patient — a full and clearly written disclosure. It states 503A FDA-registered compounding and independent batch testing, but does not name the pharmacy or the testing lab. The catalog is not one thing on evidence, and the differences matter more than the price differences. Sermorelin and tesamorelin both act on the growth-hormone axis: sermorelin is a GHRH analogue with a real mechanism and thin long-term outcome data, while tesamorelin is a stabilised GHRH analogue that is genuinely FDA-approved, but only for visceral fat reduction in HIV-associated lipodystrophy — prescribed for anything else it is off-label use of an approved drug. BPC-157 and TB-500 have interesting animal literature on soft-tissue and gut repair and essentially no controlled human outcome trials. GHK-Cu is a copper-binding tripeptide with a laboratory story in collagen synthesis and no controlled human outcome data behind the skin claims. Glutathione has essentially none. Injected NAD⁺ has no controlled human outcome trials; the oral precursors NR and NMN raise blood NAD⁺, a biomarker rather than an outcome. Individual results vary.

Pros and watch-outs

The evidence behind what Meto prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• BPC 157: what the evidence actually shows (and what it doesn't)

  The 'healing peptide' has a deep rodent literature and almost no human data. A straight read of where the science stands.

• Glutathione: the master antioxidant, and where the evidence actually is

  Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.

• GHK-Cu: the copper peptide between real skincare and overclaim

  A decades-deep molecule with a credible topical story — and systemic anti-aging claims that outrun the human data.

• Tesamorelin (Egrifta): what it's actually FDA-approved for, and the evidence

  A real, approved GHRH analog — for HIV-associated lipodystrophy specifically. What the pivotal trials showed, and why the longevity use is an extrapolation.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

How Meto compares

A few alternatives worth a look, depending on what you’re optimizing for.

• MAMaves

  NAD⁺ at a published all-in monthly price across all 50 states

  See Maves →
• LULumora

  A certified 50-state NAD⁺ program if you will complete an assessment before seeing anything

  See Lumora →
• KOKongo

  NAD⁺ injections at a published flat rate across all 50 states

  See Kongo →